StockData
Odyssey Therapeutics, Inc. logo

Odyssey Therapeutics, Inc. (ODTX) stock

ODTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026
$18.98−0.39 (-2.01%)

Close on Nov 18, 2026Market cap $912.15MP/E –Yield –

Odyssey Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$55.47M–
Q1 FY2026Mar 31, 2026-$39.78M–
Q2 FY2025Jun 30, 2025-$41.92M–
Q1 FY2025Mar 31, 2025-$39.16M–

More Odyssey Therapeutics figures

See a number that looks wrong?